(Q44748638)

English

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

scientific article published on 24 May 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Giuseppe Giaccone

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Federico Cappuzzo

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

T Ciuleanu

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

K Park

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

W Brugger

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

P Gopalakrishna

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

SATURN Investigators

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

24 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

388-394

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Cisplatin-induced activation of the EGF receptor

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR125

21 January 2018

Identifiers

10.1093/ANNONC/MDR125

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

release_aifjuuyvqnagvkgbxuuxtfkiem

1 reference

https://api.fatcat.wiki/v0/release/aifjuuyvqnagvkgbxuuxtfkiem

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21610154%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44748638&oldid=2249123487"